IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
09 07 2020
Historique:
received: 13 04 2020
accepted: 03 06 2020
pubmed: 17 6 2020
medline: 18 7 2020
entrez: 17 6 2020
Statut: epublish

Résumé

BACKGROUNDFatal cases of COVID-19 are increasing globally. We retrospectively investigated the potential of immunologic parameters as early predictors of COVID-19.METHODSA total of 1018 patients with confirmed COVID-19 were enrolled in our 2-center retrospective study. Clinical feature, laboratory test, immunological test, radiological findings, and outcomes data were collected. Univariate and multivariable logistic regression analyses were performed to evaluate factors associated with in-hospital mortality. Receiver operator characteristic (ROC) curves and survival curves were plotted to evaluate their clinical utility.RESULTSThe counts of all T lymphocyte subsets were markedly lower in nonsurvivors than in survivors, especially CD8+ T cells. Among all tested cytokines, IL-6 was elevated most significantly, with an upward trend of more than 10-fold. Using multivariate logistic regression analysis, IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/μL were found to be associated with in-hospital mortality after adjusting for confounding factors. Groups with IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/μL had a higher percentage of older and male patients as well as a higher proportion of patients with comorbidities, ventilation, intensive care unit admission, shock, and death. Furthermore, the receiver operating curve of the model combining IL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/μL) displayed a more favorable discrimination than that of the CURB-65 score. The Hosmer-Lemeshow test showed a good fit of the model, with no statistical significance.CONCLUSIONIL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/μL) are 2 reliable prognostic indicators that accurately stratify patients into risk categories and predict COVID-19 mortality.FundingThis work was supported by funding from the National Natural Science Foundation of China (no. 81772477 and 81201848).

Identifiants

pubmed: 32544099
pii: 139024
doi: 10.1172/jci.insight.139024
pmc: PMC7406244
doi:
pii:

Substances chimiques

CXCL8 protein, human 0
IL10 protein, human 0
IL6 protein, human 0
Interleukin-6 0
Interleukin-8 0
Receptors, Interleukin-2 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
ASAIO J. 2020 Jul;66(7):722-730
pubmed: 32317557
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Clin Microbiol Infect. 2015 Jun;21(6):608.e1-8
pubmed: 25704448
Clin Infect Dis. 2019 Mar 5;68(6):984-992
pubmed: 30060038
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
JAMA. 2020 Feb 7;:
pubmed: 32031570
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Clin Infect Dis. 2009 Jun 15;48(12):1796; author reply 1796-7
pubmed: 19473089
J Virol. 2016 Dec 16;91(1):
pubmed: 27795435
Clin Lab. 2008;54(5-6):179-83
pubmed: 18780664
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
Sci Immunol. 2017 Aug 4;2(14):
pubmed: 28778905
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208
pubmed: 32164089
Science. 2013 Jun 7;340(6137):1230-4
pubmed: 23618765
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452

Auteurs

Miao Luo (M)

Department of Respiratory and Critical Care Medicine, Tongji Hospital, and.

Jing Liu (J)

Department of Radiology, Wuhan Pulmonary Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Weiling Jiang (W)

Department of Respiratory and Critical Care Medicine, Tongji Hospital, and.

Shuang Yue (S)

Department of Respiratory and Critical Care Medicine, Tongji Hospital, and.

Huiguo Liu (H)

Department of Respiratory and Critical Care Medicine, Tongji Hospital, and.

Shuang Wei (S)

Department of Respiratory and Critical Care Medicine, Tongji Hospital, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH